FDA Resolves Ovation Sabril Conflict Of Interest; Sets Jan. 7-8 Advisory Panel Meeting
This article was originally published in The Pink Sheet Daily
Peripheral and CNS Drugs Advisory Committee to consider two indications for Sabril: to treat infantile spasms and as adjunctive therapy for refractory complex partial seizures in adults.
You may also be interested in...
The Longest Review: Inside Ovation’s Wait For Sabril
The anticonvulsant vigabatrin is one of a dozen products for which FDA has missed user fee deadlines so far this year. Fifteen years after the NDA first was submitted, maybe that shouldn’t be a surprise.
Advisory Committee Conflict Of Interest Policy More Flexible In Final Form
FDA releases slew of committee-related guidances, including draft on the criteria to determine when a committee meeting should be held.
FDA Panel To Review Ovation’s Sabril For Dual Epilepsy Indications
Vigabatrin set for review by Peripheral and Central Nervous System Drugs panel for seizures in adults and infantile spasms Aug. 6-7.